TNGX · Tango Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | - | $53.81M | $3.18M | $5.39M | - | $11.61M | $19.88M | $6.47M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $33.53M | - | $30.82M | $32.81M | $36.44M | - | $33.26M | $38.65M | $38.06M | - |
| SG&A | $15.23M | - | $8.92M | $11.34M | $11.48M | - | $11.22M | $10.77M | $10.66M | - |
| Total Operating Expenses | $48.77M | - | $39.74M | $44.15M | $47.92M | - | $44.48M | $49.43M | $48.73M | - |
| D&A | $463.0K | - | - | - | $622.0K | - | - | - | $625.0K | - |
| Operating Income | ($48.77M) | - | $14.07M | ($40.97M) | ($42.53M) | - | ($32.88M) | ($29.55M) | ($42.26M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $1.0K | - | ($10.0K) | $35.0K | $34.0K | - | $54.0K | $65.0K | $40.0K | - |
| Net Income | ($45.51M) | - | $15.88M | ($38.85M) | ($39.88M) | - | ($29.17M) | ($25.55M) | ($37.91M) | - |
| EPS - Basic | ($0.32) | - | $0.14 | ($0.35) | ($0.36) | - | ($0.27) | ($0.24) | ($0.35) | - |
| EPS - Diluted | ($0.32) | - | $0.13 | ($0.35) | ($0.36) | - | ($0.27) | ($0.24) | ($0.35) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $157.83M | $112.28M | $58.34M | $39.27M | $58.43M | $69.53M | $53.15M | $51.57M | $61.16M | $66.39M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $2.43M | $1.18M | $2.23M | $2.61M | $3.24M | $1.60M | $4.11M | $1.06M | $3.90M | $2.79M |
| Current Assets | $392.33M | $353.76M | $163.78M | $190.10M | $224.93M | $266.34M | $300.81M | $328.41M | $352.04M | $346.54M |
| Total Assets | $435.79M | $398.69M | $210.14M | $237.89M | $274.31M | $316.49M | $352.42M | $381.45M | $406.22M | $402.57M |
| Current Liabilities | $14.33M | $21.68M | $18.44M | $40.02M | $35.92M | $38.17M | $37.58M | $43.87M | $42.79M | $45.94M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $44.29M | $52.51M | $50.10M | $102.94M | $107.55M | $116.97M | $123.25M | $133.78M | $141.77M | $149.46M |
| Stockholders' Equity | $391.51M | $346.18M | $160.03M | $134.95M | $166.76M | $199.52M | $229.17M | $247.67M | $264.45M | $253.11M |
| Retained Earnings | ($648.67M) | ($603.15M) | ($564.40M) | ($580.29M) | ($541.43M) | ($501.56M) | ($463.89M) | ($434.72M) | ($409.17M) | ($371.26M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($44.36M) | - | - | - | ($41.70M) | - | - | - | ($37.86M) | - |
| Investing Cash Flow | $9.63M | - | - | - | $30.60M | - | - | - | ($11.20M) | - |
| Financing Cash Flow | $79.85M | - | - | - | $2.0K | - | - | - | $42.98M | - |
| CapEx | ($2.0K) | - | - | - | $51.0K | - | - | - | $195.0K | - |
| Free Cash Flow | ($44.36M) | - | - | - | ($41.75M) | - | - | - | ($38.05M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | 26.2% | -1287.9% | -788.8% | - | -283.3% | -148.7% | -653.0% | - |
| EBITDA margin | - | - | - | - | -777.2% | - | - | - | -643.3% | - |
| Net margin | - | - | 29.5% | -1221.4% | -739.5% | - | -251.3% | -128.6% | -585.9% | - |
| Free cash flow margin | - | - | - | - | -774.3% | - | - | - | -588.0% | - |
| FCF / Net income | 0.97 | - | - | - | 1.05 | - | - | - | 1.00 | - |
| R&D / Revenue | - | - | 57.3% | 1031.3% | 675.9% | - | 286.6% | 194.5% | 588.2% | - |
| SG&A / Revenue | - | - | 16.6% | 356.5% | 212.9% | - | 96.7% | 54.2% | 164.8% | - |
| Effective tax rate | - | - | -0.1% | - | - | - | - | - | - | - |
| Return on assets | -10.4% | - | 7.6% | -16.3% | -14.5% | - | -8.3% | -6.7% | -9.3% | - |
| Return on equity | -11.6% | - | 9.9% | -28.8% | -23.9% | - | -12.7% | -10.3% | -14.3% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 27.38 | 16.32 | 8.88 | 4.75 | 6.26 | 6.98 | 8.00 | 7.49 | 8.23 | 7.54 |
| Quick ratio | 27.38 | 16.32 | 8.88 | 4.75 | 6.26 | 6.98 | 8.00 | 7.49 | 8.23 | 7.54 |
| Cash ratio | 11.01 | 5.18 | 3.16 | 0.98 | 1.63 | 1.82 | 1.41 | 1.18 | 1.43 | 1.45 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.11 | 1.15 | 1.31 | 1.76 | 1.64 | 1.59 | 1.54 | 1.54 | 1.54 | 1.59 |
| Liabilities / Assets | 0.10 | 0.13 | 0.24 | 0.43 | 0.39 | 0.37 | 0.35 | 0.35 | 0.35 | 0.37 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | - | 0.26 | 0.01 | 0.02 | - | 0.03 | 0.05 | 0.02 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | 64.6x | - | - | - | - | - | - | - |
| P / B | 7.7x | - | 6.2x | 4.2x | 0.9x | - | 3.6x | 3.8x | 3.2x | - |
| P / S | - | - | 18.4x | 177.9x | 28.0x | - | 72.0x | 46.8x | 132.7x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -100.0% | - | 363.6% | -84.0% | -16.7% | - | 8.2% | 36.1% | 12.2% | - |
| Revenue CAGR (3y) | - | - | 98.1% | -44.0% | -2.2% | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -14.7% | - | - | -38.6% | -0.7% | - | -28.3% | -27.1% | -39.5% | - |
| Net income growth (YoY) | -14.1% | - | - | -52.1% | -5.2% | - | -31.0% | -23.4% | -35.4% | - |
| EPS growth (YoY) | 11.1% | - | - | -45.8% | -2.9% | - | -17.4% | -4.3% | -9.4% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -6.3% | - | - | - | -9.7% | - | - | - | -7.1% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 134.8% | 73.5% | -30.2% | -45.5% | -36.9% | -21.2% | -17.1% | 16.3% | 16.4% | 1.5% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$62.38M totalCollaboration Revenue$62.38M · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Tango Therapeutics against the 5 most active filers in the same SIC group.